International Clinical Trial: Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07125872) titled 'Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma' on Aug. 11.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: ImmunityBio, Inc.

Condition: Relapsed B-Cell Non Hodgkin Lymphoma

Intervention: Biological: CD19 t-haNK- IV Administration

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 19, 2025

Target Sample Size: 20

To know more, visit https://cli...